Skip to main content
KYTX
NASDAQ Life Sciences

Kyverna Completes First-Ever Autoimmune CAR-T BLA Filing, Seeks Priority Review in Stiff Person Syndrome

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.2
Mkt Cap
$316.638M
52W Low
$4.495
52W High
$13.67
52W Position info
16% above low
Off High info
62% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

KYTX sits 16% above its 52-week low of $4.495.

Summary

Kyverna finished its rolling BLA for miv-cel in stiff person syndrome and asked the FDA for priority review under its RMAT designation. If approved, miv-cel would be the first therapy approved for SPS and the first CAR-T approved in autoimmune disease — a genuine first-in-class position. The filing rests on the KYSA-8 registrational data reported in September and the one-year durability results presented at MS Toronto in October, so the clinical package is already public; what's new is that the application is now in the FDA's hands. The company is staffing up commercial leadership and field infrastructure ahead of a potential 2027 launch. Q3 cash stood at $170.6M with runway into 2028, and the net loss was $41.9M ($0.68 per share). Kyverna also shelved the KYV-102 program to concentrate spending on miv-cel. Next hard checkpoint is FDA acceptance and the priority-review decision; gMG enrollment is guided to finish mid-2027.

At the time of this announcement, KYTX was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $316.6M. The 52-week trading range was $4.50 to $13.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

KYTX - Latest Insights

KYTX
Nov 12, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.20
Real-time Price: $5.84 info
Change: +$0.640 (+12%) info
Market Cap: $316.638M info
KYTX
Oct 23, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.43
Real-time Price: $5.84 info
Change: +$0.410 (+8%) info
Market Cap: $316.638M info
KYTX
Sep 24, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.05
Real-time Price: $5.84 info
Change: -$1.21 (-17%) info
Market Cap: $316.638M info
KYTX
Sep 24, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $7.19
Real-time Price: $5.84 info
Change: -$1.35 (-19%) info
Market Cap: $316.638M info
KYTX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.02
Real-time Price: $5.84 info
Change: -$2.18 (-27%) info
Market Cap: $316.638M info